Abbott Laboratories(ABT)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Devices
Abbott Laboratories logo

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Latest News & Analysis

Abbott (ABT) stock analysis: Volt PFA approval, TriClip trial success, dividend aristocrat status, and Q1 2025 earnings outlook for investors.
Apr 2, 2025

Abbott (ABT): Volt PFA Approval, TriClip Success, and Market Outlook

Abbott Laboratories (ABT) navigates market volatility with Volt PFA approval, TriClip success, and a consistent dividend history, making it a stable investment.

Read more →
Abbott (ABT) stock surges following Volt™ PFA system CE Mark and FDA IDE approval for Coronary IVL system; dividend yield analysis, AI integration, and future investment outlook.
Mar 27, 2025

Abbott (ABT): PFA Approval, Coronary IVL System, and Market Outlook

Abbott Laboratories (ABT) gains momentum with CE Mark approval for Volt™ PFA and FDA IDE nod for Coronary IVL, bolstering its cardiovascular portfolio.

Read more →
Abbott Laboratories (ABT) analysis: FDA approval for coronary IVL system, market impact, AI investments, and future growth prospects.
Mar 25, 2025

Abbott (ABT): FDA Approval, Market Impact, and Future Growth

Analysis of Abbott Laboratories (ABT): FDA approval for Coronary IVL System, AI initiatives, dividend growth, and strategic focus on diabetes care and weight-loss.

Read more →
Abbott Laboratories: IVL therapy, weight loss solutions, and AI-driven advancements fueling growth in the healthcare sector. Stay informed about Abbott's strategic moves.
Mar 24, 2025

Abbott Laboratories: Coronary IVL, Weight Loss, and AI Driving Growth

Abbott Laboratories is strategically positioned for growth through medical devices, expansion into weight-loss, and AI integration. Dividend payouts and financial stability enhance its appeal.

Read more →
Abbott Laboratories: Growth drivers, dividend reliability, and market outlook for 2025. Learn about ABT's FreeStyle Libre, weight-loss treatments, and financial performance.
Mar 17, 2025

Abbott (ABT): Growth, Dividends, and Market Outlook 2025

Abbott Laboratories (ABT) navigates market dynamics with strategic expansions, FreeStyle Libre advancements, and dividend reliability. A detailed analysis for investors.

Read more →
Abbott Laboratories: Analysis of earnings, dividends, growth potential, and competitive landscape.
Mar 10, 2025

Abbott Laboratories (ABT): Earnings, Dividends, and Growth Analysis

A deep dive into Abbott Laboratories' recent performance, dividend aristocrat status, and growth prospects. Discover how strategic initiatives and market dynamics shape ABT's future.

Read more →
ABT Stock Analysis: Intraday performance, financial metrics, and future outlook for Abbott Laboratories. Data-driven insights for investors.
Mar 5, 2025

Abbott Laboratories: Intraday Market Update - March 5, 2025

Intraday update on Abbott Laboratories (ABT) with key financial metrics, dividend news, strategic moves, and market trends from credible sources.

Read more →
Abbott Laboratories stock analysis: Growth drivers, market trends, and 2025 outlook. Is ABT a buy?
Feb 28, 2025

Abbott Laboratories: Analyzing Growth Drivers and Future Outlook

Abbott Laboratories (ABT) navigates 2025 with strong performance, driven by FreeStyle Libre and molecular diagnostics, despite FX headwinds. Dividend Aristocrat status enhances investor appeal.

Read more →
Abbott (ABT) Stock Analysis: Dividend King, Diabetes Care Leadership, and Molecular Diagnostics Growth in 2025. Investment insights and financial outlook.
Feb 27, 2025

Abbott (ABT) in 2025: Dividend King, Diabetes Care Leader

Abbott Laboratories (ABT) shows strong 2025 performance driven by dividends, diabetes care, and diagnostics growth, despite FX risks. A detailed analysis follows.

Read more →
Abbott Laboratories (ABT) stock analysis: Growth drivers, diabetes care, molecular diagnostics, and dividend performance.
Feb 26, 2025

Abbott Laboratories (ABT): Growth, Dividends, and Market Leadership

Comprehensive analysis of Abbott Laboratories (ABT): exploring diabetes care innovations, molecular diagnostics growth, dividend consistency, and future outlook.

Read more →
Abbott Laboratories: Growth in Diabetes Care and Molecular Diagnostics - Stock Analysis
Feb 25, 2025

Abbott Laboratories (ABT): Navigating Growth in Diabetes Care & Diagnostics

**Abbott Laboratories (ABT) demonstrates resilience and growth potential.** Driven by FreeStyle Libre and expansion in molecular diagnostics, the company maintains a steady climb.

Read more →
Abbott Laboratories: Dividend Stability, Diabetes Care Growth, and Molecular Diagnostics Opportunities in 2025
Feb 24, 2025

Abbott Laboratories: Growth Drivers, Market Trends, and Future Outlook

Abbott Laboratories navigates a dynamic healthcare landscape with consistent dividends, FreeStyle Libre growth, and molecular diagnostics opportunities. A comprehensive analysis of ABT's market position.

Read more →
Abbott's Steady Course: Dividends, Diabetes Care Growth, and Diagnostics Expansion
Feb 21, 2025

Abbott Laboratories: Dividends, Diabetes Care & Market Trends

Abbott continues to deliver consistent dividends, robust diabetes care growth, and expanding diagnostics in a competitive healthcare landscape.

Read more →
Abbott Laboratories (ABT) stock analysis: Market performance, growth drivers, and investment opportunities in diabetes care and molecular diagnostics.
Feb 21, 2025

Abbott Laboratories: Navigating Growth in Diabetes Care

Abbott Laboratories demonstrates resilience amid market volatility, driven by growth in diabetes care and strategic market expansion. ABT stock increases +0.79%.

Read more →
Futuristic medical lab with robotic arm analyzing a sample, representing advancements in healthcare diagnostics.
Feb 18, 2025

Abbott Laboratories: Navigating Growth in Diagnostics, Diabetes Care, and Dividends

A comprehensive data-driven analysis of Abbott’s Q4 performance, R&D investments, and market trends shaping its future.

Read more →